Sara López‐Tarruella

Author

Hospital General Universitario Gregorio Marañón ORCID

Also Known As

Cortes, Javier, López-Tarruella S, López-Tarruella, Sara, Puente Vázquez, Javier, S Lopez-Tarruella, S López-Tarruella, S. Cobo, S. Lopez Tarruella, S. Lopez-Tarruella, S. Lopez-Tarruella Cobo

259

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Hospital General Universitario Gregorio Marañón Hospital Clínico San Carlos Centro de Investigación Biomédica en Red de Cáncer University of North Carolina at Chapel Hill GEICAM – Spanish Breast Cancer Group

About

Sara López‐Tarruella is an author at Hospital General Universitario Gregorio Marañón specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	878
2	Health Sciences	3	3	179
3	Nursing	2	2	50
4	Public Health	2	2	31
5	Biostatistics	2	2	119

Sara López‐Tarruella

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts Priyanka Sharma, Sara López‐Tarruella, José Á. García-Sáenz, Clinical Cancer Research	2016	137
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial Sònia Pernas, Miguel Martín, Peter A. Kaufman, The Lancet Oncology Breast OncologyOncologyMedicineBreast CancerPharmacotherapy	2018	133
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel Priyanka Sharma, Sara López‐Tarruella, José Á. García-Sáenz, Clinical Cancer Research	2018	125
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy Mario Giuliano, Huizhong Hu, Yen-Chao Wang, Clinical Cancer Research	2015	118
Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial Soraya Casla, Sara López‐Tarruella, Yolanda Jerez, Breast Cancer Research and Treatment Supervised Physical ExercisePhysical ActivityKinesiologyBreast OncologyExercise	2015	110
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification Isabel Echavarría, Sara López‐Tarruella, Antoni C. Picornell, Clinical Cancer Research Breast OncologyReliable PredictorsMedicineMetronomic TherapyNeoadjuvant Carboplatin	2018	107
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors Iván Márquez‐Rodas, Federico Longo, María E. Rodríguez-Ruiz, Science Translational Medicine	2020	80
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer Miguel Martín, Atocha Romero, Maggie C.U. Cheang, Breast Cancer Research and Treatment Breast OncologyMedicinePathologyPrimary Breast CancerCancer Genomics	2011	72
Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series Antoni C. Picornell, Isabel Echavarría, Enrique L. Álvarez, BMC Genomics	2019	57
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. Elgene Lim, Komal Jhaveri, José Alejandro Pérez Fidalgo, Journal of Clinical Oncology Phase Ib StudyBreast OncologyOncologyMedicineMetronomic Therapy	2020	56

Page 1